{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:33:43Z","timestamp":1790364823746,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Latent infection of Epstein-Barr virus (EBV) is associated with a poor prognosis in patients with B cell malignancy. We examined whether dasatinib, a multi kinase inhibitor, which is broadly used for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia is effective on EBV-positive B cell malignancies, using lymphoblastoid cell lines (LCLs) <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. As a result, <jats:italic>in vitro<\/jats:italic> experiments showed that dasatinib induced cell death of the EBV-LCLs which was not accompanied with a lytic reactivation of EBVs. To evaluate the effectiveness in EBV latency type III represented by immunodeficiency lymphoma, LCL-inoculated immunodeficient NOD\/shi-<jats:italic>scid<\/jats:italic>\/<jats:italic>Il2rg<\/jats:italic><jats:sup>nul<\/jats:sup> (NOG) mice were treated with dasatinib. However, <jats:italic>in vivo<\/jats:italic> experiments revealed that dasatinib treatment exacerbated tumor cell infiltration into the spleen of LCL-inoculated NOG mice, whereas tumor size at the inoculated site was not affected by the treatment. These results suggest that dasatinib exacerbates the pathogenesis at least in some situations although the drug is effective <jats:italic>in vitro<\/jats:italic>. Hence, we should carefully examine a possibility of dasatinib repositioning for EBV<jats:sup>+<\/jats:sup> B cell malignancies.<\/jats:p>","DOI":"10.1038\/s41598-020-61300-y","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T11:02:46Z","timestamp":1583751766000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Dasatinib exacerbates splenomegaly of mice inoculated with Epstein-Barr virus-infected lymphoblastoid cell lines"],"prefix":"10.1038","volume":"10","author":[{"given":"Ryutaro","family":"Kotaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara Yukie","family":"Kikuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-Ichi","family":"Imadome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,9]]},"reference":[{"key":"61300_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/2042-4280-2-8","volume":"2","author":"CP Fox","year":"2011","unstructured":"Fox, C. P., Shannon-Lowe, C. & Rowe, M. Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferations. Herpesviridae 2, 8, https:\/\/doi.org\/10.1186\/2042-4280-2-8 (2011).","journal-title":"Herpesviridae"},{"key":"61300_CR2","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1084\/jem.20161846","volume":"214","author":"SG Tangye","year":"2017","unstructured":"Tangye, S. G., Palendira, U. & Edwards, E. S. Human immunity against EBV-lessons from the clinic. J. Exp. Med. 214, 269\u2013283, https:\/\/doi.org\/10.1084\/jem.20161846 (2017).","journal-title":"J. Exp. Med."},{"key":"61300_CR3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1074-7613(00)80622-6","volume":"9","author":"GJ Babcock","year":"1998","unstructured":"Babcock, G. J., Mark Volk, L. L. D. & Thorley-Lawson., D. A. EBV Persistence in Memory B Cells In Vivo. Immun. 9, 395\u2013404 (1998).","journal-title":"Immun."},{"key":"61300_CR4","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.4049\/jimmunol.165.6.2975","volume":"165","author":"AM Joseph","year":"2000","unstructured":"Joseph, A. M., Babcock, G. J. & Thorley-Lawson, D. A. EBV Persistence Involves Strict Selection of Latently Infected B Cells. J. Immunology 165, 2975\u20132981, https:\/\/doi.org\/10.4049\/jimmunol.165.6.2975 (2000).","journal-title":"J. Immunology"},{"key":"61300_CR5","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.1128\/JVI.71.7.4882-4891.1997","volume":"71","author":"EM Miyashita","year":"1997","unstructured":"Miyashita, E. M., Yang, B., Babcock, G. J. & Thorley-Lawson, D. A. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J. Virol. 71, 4882\u20134891 (1997).","journal-title":"J. Virol."},{"key":"61300_CR6","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1200\/JCO.2008.20.5138","volume":"27","author":"A Diepstra","year":"2009","unstructured":"Diepstra, A. et al. Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin\u2019s lymphoma predicts adverse outcome in older adult patients. J. Clin. Oncol. 27, 3815\u20133821, https:\/\/doi.org\/10.1200\/JCO.2008.20.5138 (2009).","journal-title":"J. Clin. Oncol."},{"key":"61300_CR7","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1182\/blood-2004-09-3759","volume":"106","author":"RF Jarrett","year":"2005","unstructured":"Jarrett, R. F. et al. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study. Blood 106, 2444\u20132451, https:\/\/doi.org\/10.1182\/blood-2004-09-3759 (2005).","journal-title":"Blood"},{"key":"61300_CR8","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1007\/s00277-012-1464-8","volume":"91","author":"YW Koh","year":"2012","unstructured":"Koh, Y. W., Yoon, D. H., Suh, C. & Huh, J. Impact of the Epstein-Barr virus positivity on Hodgkin\u2019s lymphoma in a large cohort from a single institute in Korea. Ann. Hematol. 91, 1403\u20131412, https:\/\/doi.org\/10.1007\/s00277-012-1464-8 (2012).","journal-title":"Ann. Hematol."},{"key":"61300_CR9","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/cas.12467","volume":"105","author":"A Sato","year":"2014","unstructured":"Sato, A. et al. Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era. Cancer Sci. 105, 1170\u20131175, https:\/\/doi.org\/10.1111\/cas.12467 (2014).","journal-title":"Cancer Sci."},{"key":"61300_CR10","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/nrc1452","volume":"4","author":"LS Young","year":"2004","unstructured":"Young, L. S. & Rickinson, A. B. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4, 757\u2013768, https:\/\/doi.org\/10.1038\/nrc1452 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"61300_CR11","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1038\/onc.2016.380","volume":"36","author":"L Wang","year":"2017","unstructured":"Wang, L. et al. LMP1 signaling pathway activates IRF4 in latent EBV infection and a positive circuit between PI3K and Src is required. Oncogene 36, 2265\u20132274, https:\/\/doi.org\/10.1038\/onc.2016.380 (2017).","journal-title":"Oncogene"},{"key":"61300_CR12","doi-asserted-by":"publisher","first-page":"9672","DOI":"10.1128\/JVI.01435-13","volume":"87","author":"L Wang","year":"2013","unstructured":"Wang, L. & Ning, S. Interferon regulatory factor 4 is activated through c-Src-mediated tyrosine phosphorylation in virus-transformed cells. J. Virol. 87, 9672\u20139679, https:\/\/doi.org\/10.1128\/JVI.01435-13 (2013).","journal-title":"J. Virol."},{"key":"61300_CR13","doi-asserted-by":"publisher","first-page":"11963","DOI":"10.1073\/pnas.95.20.11963","volume":"95","author":"W Kulwichit","year":"1998","unstructured":"Kulwichit, W. et al. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc. Natl Acad. Sci. USA 95, 11963\u201311968 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"61300_CR14","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.cell.2011.12.031","volume":"148","author":"B Zhang","year":"2012","unstructured":"Zhang, B. et al. Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model. Cell 148, 739\u2013751, https:\/\/doi.org\/10.1016\/j.cell.2011.12.031 (2012).","journal-title":"Cell"},{"key":"61300_CR15","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1128\/JVI.74.3.1101-1113.2000","volume":"74","author":"RG Caldwell","year":"2000","unstructured":"Caldwell, R. G., Brown, R. C. & Longnecker, R. Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice. J. Virol. 74, 1101\u20131113 (2000).","journal-title":"J. Virol."},{"key":"61300_CR16","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1074-7613(00)80623-8","volume":"9","author":"RG Caldwell","year":"1998","unstructured":"Caldwell, R. G., Wilson, J. B., Anderson, S. J. & Longnecker, R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immun. 9, 405\u2013411 (1998).","journal-title":"Immun."},{"key":"61300_CR17","doi-asserted-by":"publisher","first-page":"17945","DOI":"10.1073\/pnas.0907994106","volume":"106","author":"KT Bieging","year":"2009","unstructured":"Bieging, K. T., Amick, A. C. & Longnecker, R. Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis. Proc. Natl Acad. Sci. USA 106, 17945\u201317950, https:\/\/doi.org\/10.1073\/pnas.0907994106 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"61300_CR18","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1038\/onc.2008.492","volume":"28","author":"R Bultema","year":"2009","unstructured":"Bultema, R., Longnecker, R. & Swanson-Mungerson, M. Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis. Oncogene 28, 1471\u20131476, https:\/\/doi.org\/10.1038\/onc.2008.492 (2009).","journal-title":"Oncogene"},{"key":"61300_CR19","doi-asserted-by":"publisher","first-page":"4481","DOI":"10.1128\/JVI.73.5.4481-4484.1999","volume":"73","author":"C Kaiser","year":"1999","unstructured":"Kaiser, C. et al. The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J. Virol. 73, 4481\u20134484 (1999).","journal-title":"J. Virol."},{"key":"61300_CR20","doi-asserted-by":"publisher","unstructured":"Sinclair, A. J., Wasil, L. R., Tomaszewski, M. J., Hoji, A. & Rowe, D. T. The Effect of Epstein-Barr Virus Latent Membrane Protein 2 Expression on the Kinetics of Early B Cell Infection. PLoS ONE 8, https:\/\/doi.org\/10.1371\/journal.pone.0054010 (2013).","DOI":"10.1371\/journal.pone.0054010"},{"key":"61300_CR21","doi-asserted-by":"publisher","first-page":"8520","DOI":"10.1128\/jvi.00843-08","volume":"82","author":"M Rovedo","year":"2008","unstructured":"Rovedo, M. & Longnecker, R. Epstein-Barr Virus Latent Membrane Protein 2A Preferentially Signals through the Src Family Kinase Lyn. J. Virology 82, 8520\u20138528, https:\/\/doi.org\/10.1128\/jvi.00843-08 (2008).","journal-title":"J. Virology"},{"key":"61300_CR22","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"LJ Lombardo","year":"2004","unstructured":"Lombardo, L. J. et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658\u20136661, https:\/\/doi.org\/10.1021\/jm049486a (2004).","journal-title":"J. Med. Chem."},{"key":"61300_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","volume":"305","author":"NP Shah","year":"2004","unstructured":"Shah, N. P. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Sci. 305, 399\u2013401, https:\/\/doi.org\/10.1126\/science.1099480 (2004).","journal-title":"Sci."},{"key":"61300_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.antiviral.2012.05.003","volume":"95","author":"JL Dargart","year":"2012","unstructured":"Dargart, J. L., Fish, K., Gordon, L. I., Longnecker, R. & Cen, O. Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A. Antivir. Res. 95, 49\u201356, https:\/\/doi.org\/10.1016\/j.antiviral.2012.05.003 (2012).","journal-title":"Antivir. Res."},{"key":"61300_CR25","doi-asserted-by":"publisher","first-page":"16981","DOI":"10.1073\/pnas.1905239116","volume":"116","author":"C Scuoppo","year":"2019","unstructured":"Scuoppo, C. et al. Repurposing dasatinib for diffuse large B cell lymphoma. Proc. Natl Acad. Sci. USA 116, 16981\u201316986, https:\/\/doi.org\/10.1073\/pnas.1905239116 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"61300_CR26","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1634\/theoncologist.2008-0036","volume":"13","author":"A Carbone","year":"2008","unstructured":"Carbone, A., Gloghini, A. & Dotti, G. EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist 13, 577\u2013585, https:\/\/doi.org\/10.1634\/theoncologist.2008-0036 (2008).","journal-title":"Oncologist"},{"key":"61300_CR27","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.molonc.2009.01.002","volume":"3","author":"TP Green","year":"2009","unstructured":"Green, T. P. et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Mol. Oncol. 3, 248\u2013261, https:\/\/doi.org\/10.1016\/j.molonc.2009.01.002 (2009).","journal-title":"Mol. Oncol."},{"key":"61300_CR28","doi-asserted-by":"publisher","first-page":"6465","DOI":"10.1021\/jm060434q","volume":"49","author":"LF Hennequin","year":"2006","unstructured":"Hennequin, L. F. et al. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src\/Abl kinase inhibitor. J. Med. Chem. 49, 6465\u20136488, https:\/\/doi.org\/10.1021\/jm060434q (2006).","journal-title":"J. Med. Chem."},{"key":"61300_CR29","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.virol.2016.10.015","volume":"500","author":"R Incrocci","year":"2017","unstructured":"Incrocci, R. et al. Epstein-Barr Virus Latent Membrane Protein 2A (LMP2A) enhances IL-10 production through the activation of Bruton\u2019s tyrosine kinase and STAT3. Virology 500, 96\u2013102, https:\/\/doi.org\/10.1016\/j.virol.2016.10.015 (2017).","journal-title":"Virology"},{"key":"61300_CR30","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1006\/viro.2001.1187","volume":"291","author":"M Merchant","year":"2001","unstructured":"Merchant, M. & Longnecker, R. LMP2A survival and developmental signals are transmitted through Btk-dependent and Btk-independent pathways. Virology 291, 46\u201354, https:\/\/doi.org\/10.1006\/viro.2001.1187 (2001).","journal-title":"Virology"},{"key":"61300_CR31","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.exphem.2015.01.008","volume":"43","author":"MP Oksvold","year":"2015","unstructured":"Oksvold, M. P. et al. The targeting of human and mouse B lymphocytes by dasatinib. Exp. Hematol. 43, 352\u2013363 e354, https:\/\/doi.org\/10.1016\/j.exphem.2015.01.008 (2015).","journal-title":"Exp. Hematol."},{"key":"61300_CR32","doi-asserted-by":"publisher","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg, L. A. et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl Acad. Sci. 107, 13075\u201313080, https:\/\/doi.org\/10.1073\/pnas.1004594107 (2010).","journal-title":"Proc. Natl Acad. Sci."},{"key":"61300_CR33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/cmdc.200600221","volume":"2","author":"Z Pan","year":"2007","unstructured":"Pan, Z. et al. Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase. ChemMedChem 2, 58\u201361, https:\/\/doi.org\/10.1002\/cmdc.200600221 (2007).","journal-title":"ChemMedChem"},{"key":"61300_CR34","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.4049\/jimmunol.1600915","volume":"197","author":"E Ten Hacken","year":"2016","unstructured":"Ten Hacken, E. et al. Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia. J. Immunol. 197, 2522\u20132531, https:\/\/doi.org\/10.4049\/jimmunol.1600915 (2016).","journal-title":"J. Immunol."},{"key":"61300_CR35","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1126\/science.283.5403.845","volume":"283","author":"A Peled","year":"1999","unstructured":"Peled, A. et al. Dependence of human stem cell engraftment and repopulation of NOD\/SCID mice on CXCR4. Sci. 283, 845\u2013848, https:\/\/doi.org\/10.1126\/science.283.5403.845 (1999).","journal-title":"Sci."},{"key":"61300_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/b978-0-12-411638-2.00002-1","volume":"124","author":"S Chatterjee","year":"2014","unstructured":"Chatterjee, S., Behnam Azad, B. & Nimmagadda, S. The intricate role of CXCR4 in cancer. Adv. cancer Res. 124, 31\u201382, https:\/\/doi.org\/10.1016\/b978-0-12-411638-2.00002-1 (2014).","journal-title":"Adv. cancer Res."},{"key":"61300_CR37","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1182\/blood-2017-07-794529","volume":"131","author":"H Higuchi","year":"2018","unstructured":"Higuchi, H. et al. Role of exosomes as a proinflammatory mediator in the development of EBV-associated lymphoma. Blood 131, 2552\u20132567, https:\/\/doi.org\/10.1182\/blood-2017-07-794529 (2018).","journal-title":"Blood"},{"key":"61300_CR38","doi-asserted-by":"publisher","first-page":"4233","DOI":"10.1182\/blood-2007-07-099226","volume":"111","author":"K Movahedi","year":"2008","unstructured":"Movahedi, K. et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111, 4233\u20134244, https:\/\/doi.org\/10.1182\/blood-2007-07-099226 (2008).","journal-title":"Blood"},{"key":"61300_CR39","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/path.4446","volume":"235","author":"MJ Moreno","year":"2015","unstructured":"Moreno, M. J. et al. CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival. J. Pathol. 235, 445\u2013455, https:\/\/doi.org\/10.1002\/path.4446 (2015).","journal-title":"J. Pathol."},{"key":"61300_CR40","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3389\/fonc.2014.00349","volume":"4","author":"K De Veirman","year":"2014","unstructured":"De Veirman, K. et al. Myeloid-derived suppressor cells as therapeutic target in hematological malignancies. Front. Oncol. 4, 349, https:\/\/doi.org\/10.3389\/fonc.2014.00349 (2014).","journal-title":"Front. Oncol."},{"key":"61300_CR41","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3389\/fimmu.2018.00398","volume":"9","author":"V Fleming","year":"2018","unstructured":"Fleming, V. et al. Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression. Front. Immunol. 9, 398, https:\/\/doi.org\/10.3389\/fimmu.2018.00398 (2018).","journal-title":"Front. Immunol."},{"key":"61300_CR42","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrmicro2070","volume":"7","author":"T Bergsbaken","year":"2009","unstructured":"Bergsbaken, T., Fink, S. L. & Cookson, B. T. Pyroptosis: host cell death and inflammation. Nat. reviews. Microbiology 7, 99\u2013109, https:\/\/doi.org\/10.1038\/nrmicro2070 (2009).","journal-title":"Nat. reviews. Microbiology"},{"key":"61300_CR43","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/nri.2016.147","volume":"17","author":"I Jorgensen","year":"2017","unstructured":"Jorgensen, I., Rayamajhi, M. & Miao, E. A. Programmed cell death as a defence against infection. Nat. Rev. Immunol. 17, 151\u2013164, https:\/\/doi.org\/10.1038\/nri.2016.147 (2017).","journal-title":"Nat. Rev. Immunol."},{"key":"61300_CR44","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nrm3683","volume":"14","author":"D Ofengeim","year":"2013","unstructured":"Ofengeim, D. & Yuan, J. Regulation of RIP1 kinase signalling at the crossroads of inflammation and cell death. Nat. reviews. Mol. Cell Biol. 14, 727\u2013736, https:\/\/doi.org\/10.1038\/nrm3683 (2013).","journal-title":"Nat. reviews. Mol. Cell Biol."},{"key":"61300_CR45","doi-asserted-by":"publisher","unstructured":"Kosowicz, J. G. et al. Drug Modulators of B Cell Signaling Pathways and Epstein-Barr Virus Lytic Activation. J Virol 91, https:\/\/doi.org\/10.1128\/jvi.00747-17 (2017).","DOI":"10.1128\/jvi.00747-17"},{"key":"61300_CR46","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/0042-6822(79)90490-2","volume":"95","author":"G Wilson","year":"1979","unstructured":"Wilson, G. & Miller, G. Recovery of Epstein-Barr virus from nonproducer neonatal human lymphoid cell transformants. Virology 95, 351\u2013358 (1979).","journal-title":"Virology"},{"key":"61300_CR47","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/his.13106","volume":"70","author":"J Carreras","year":"2017","unstructured":"Carreras, J. et al. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS). Histopathology 70, 595\u2013621, https:\/\/doi.org\/10.1111\/his.13106 (2017).","journal-title":"Histopathology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61300-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61300-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61300-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T08:19:45Z","timestamp":1670314785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-61300-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,9]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["61300"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-61300-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,9]]},"assertion":[{"value":"7 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.K. has the subsequent financial relationship: Leadership position\/advisory role for Janssen Pharmaceutical. The other authors have no conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4355"}}